Status:
COMPLETED
Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
Lead Sponsor:
SK Life Science, Inc.
Conditions:
Seizures
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the long-term safety of RWJ-333369 at doses between 200-800 mg/day in Korean and Japanese patients who have completed the preceding study (333369-KJ-02).
Detailed Description
Despite the introduction of new antiepileptic drugs into overseas clinical settings after 1990's, there still exist those patients who cannot control seizures, and thus the advent of newer antiepilept...
Eligibility Criteria
Inclusion
- Patients in the preceding study (333369-KJ-02) who have completed Double-Blind Treatment Phase of preceding study
Exclusion
- Considered ineligible as study patients by the investigator
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00697918
Start Date
March 1 2008
End Date
April 1 2009
Last Update
January 16 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.